These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37897950)

  • 1. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer.
    Sayadmanesh A; Yekehfallah V; Valizadeh A; Abedelahi A; Shafaei H; Shanehbandi D; Basiri M; Baradaran B
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111093. PubMed ID: 37897950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
    Yu S; Yi M; Qin S; Wu K
    Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and strategies for safe chimeric antigen receptor T-cell activity control.
    Stock S; Klüver AK; Fertig L; Menkhoff VD; Subklewe M; Endres S; Kobold S
    Int J Cancer; 2023 Nov; 153(10):1706-1725. PubMed ID: 37350095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Next-Generation CAR-T Cells for Better Toxicity Management.
    Andrea AE; Chiron A; Bessoles S; Hacein-Bey-Abina S
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy.
    Zhang E; Xu H
    J Hematol Oncol; 2017 Jan; 10(1):1. PubMed ID: 28049484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.
    Ercilla-Rodríguez P; Sánchez-Díez M; Alegría-Aravena N; Quiroz-Troncoso J; Gavira-O'Neill CE; González-Martos R; Ramírez-Castillejo C
    Front Immunol; 2024; 15():1333150. PubMed ID: 39091493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.
    Giardino Torchia ML; Gilbreth R; Merlino A; Sult E; Monks N; Chesebrough J; Tammali R; Chu N; Tong J; Meekin J; Schifferli K; Vashisht K; DaCosta K; Clarke L; Gesse C; Yao XT; Bridges C; Moody G
    Cytotherapy; 2022 Jul; 24(7):720-732. PubMed ID: 35570170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.
    Sun W; Liang AB; Huang H; Huang XJ
    Haematologica; 2023 Aug; 108(8):2011-2028. PubMed ID: 36794504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
    Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
    J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
    Kim SJ; Yoon SE; Kim WS
    Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
    Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
    Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of chimeric antigen receptor T-cells in lymphoma.
    Anderson JK; Mehta A
    Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.